🔥Telegram İfşa

With solid tumors representing ~90% of cancers, Dispatch Bio is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform to help create a world where all #cancer patients can be cured. Learn more: dispatchbio.com/news/dispatch-…

Hear from our CEO, Sabah Öney, on The Long Run podcast: “CAR-T Cells Against Solid Tumors.” He shares more on Dispatch’s beginning, our unique #immunotherapy approach, how we aim to make an impact for patients with solid tumors and more. Listen below.

Cancer research needs us all. At Dispatch, we're committed to pushing the boundaries of science to expand treatments & bring new hope to patients. This #WorldCancerResearchDay, learn how we’re working to transform #cancer treatment for solid tumors: dispatchbio.com/science/

Please welcome Mauro Avanzi, M.D., Ph.D., as our CMO. His deep clinical development experience will be instrumental as he drives our growing pipeline of therapeutic candidates & prepares for our 1st programs to enter the clinic next year. Details: dispatchbio.com/news/dispatch-…

Today, we announced two upcoming presentations at #SITC25. We look forward to engaging with the immuno-oncology community & to providing more detail on our scientific approach. Learn more: dispatchbio.com/news/dispatch-…

Immunotherapy in solid tumors has been limited by few tumor-specific targets & a suppressive tumor microenvironment. Our approach is designed to overcome these barriers using a tumor-specific virus to expand the curative potential for #cancer patients.

Today, we unveiled our first therapeutic program, DISP-10, & preclinical findings that highlight the potential of both DISP-10 & our Flare platform at #SITC25. Listen below as our co-founder + CPO & CSO discuss our approach. Learn more here: dispatchbio.com/news/dispatch-…

Today, we announced a clinical supply & collaboration agreement with Bristol Myers Squibb to support the development of our first therapeutic program, DISP-10, underscoring the potential of our Flare platform & scientific approach. Read more here. dispatchbio.com/news/dispatch-…

This week at #SITC25, we unveiled our first therapeutic program, DISP-10. The preclinical findings underscore DISP-10’s potential to make a meaningful impact for patients. Listen below as our CSO describes DISP-10, & co-founder + CPO shares key takeaways.

Congrats to Dispatch co-founder Carl June & founding chairman Jeff Marrazzo on being named among @PhillyMag’s 150 Most Influential Philadelphians! We’re proud to have such pioneering minds shaping our mission & driving innovation. View the full list below. phillymag.com/influential-ph…